Genetic Engineering News and Research

RSS

African health experts urge immediate action over new Ebola cases

African health experts have called for an immediate and coordinated response from pan-African authorities after new cases of the Bundibugyo Ebola virus emerged in Kenya and Nigeria.

26 Oct 2026

New gene-editing platform gives doctors control over cell therapies

An Australian clinician-led research team has developed a gene-editing platform that could give doctors more control over cell therapies, making them more practical for patients with complex immune conditions.

20 Oct 2026

Researchers identify molecular pathway that improves ultrasound-based bone defect healing

Researchers from Capital Medical University, Beijing, China, have identified a CaN/NFATC3/Id3/E2A/Bmp4 signaling pathway that helps explain how low-intensity pulsed ultrasound (LIPUS) promotes bone regeneration.

15 Oct 2026

Streamlining CRISPR workflows, from editing to analysis

INTEGRA's automated solutions optimize CRISPR workflows, enhancing gene editing efficiency and accelerating the path to innovative therapeutic developments.

From INTEGRA Biosciences 30 Sep 2026

MolBoolean™ measures free and bound proteins in the same experiment

Atlas Antibodies has launched MolBoolean™, a new in situ proximity assay. It detects free protein A, free protein B, and the A–B complex together in fixed cells and tissue.

From Atlas Antibodies AB 30 Sep 2026

CRISPR activation library uncovers gene driving lymphoma growth and resistance

Researchers have uncovered a previously unknown gene causing resistance to a leading blood cancer drug and several genes that accelerate lymphoma growth by using a powerful new CRISPR activation library.

18 Sep 2026

Pig kidney xenotransplantation offers a bridge for patients awaiting human donor kidneys

In January 2026, Tim Andrews, who had received a genetically edited pig kidney in January 2025, became the recipient of a human kidney.

3 Sep 2026

Scientists uncover cellular mechanism behind congenital heart defects

Congenital heart disease affects approximately two in every 100 newborns globally. But why do they occur?

4 Aug 2026

Scientists discover master molecular switch for ginseng saponin production

Sanchi ginseng (Panax notoginseng) is a cornerstone of traditional Chinese medicine, prized for its saponins-bioactive compounds with anti-inflammatory, cardiovascular, and anticancer properties.

24 Jul 2026

Peacemaker immune cells offer new hope for restoring immune tolerance

'Peacemaker' immune cells could help treat diseases ranging from type 1 diabetes to neurodegeneration by restoring immune tolerance, according to a new paper in Frontiers in Science.

25 Jun 2026

New method generates renewable supply of progenitor immune cells

In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages.

19 Jun 2026

Brazilian researchers identify cell molecule that drives cancer progression

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.

18 Jun 2026

Engineered phages use molecular anchors to enter human cells

The study identified phage surface proteins acting as molecular anchors. These proteins confer phages ith the ability to attach to human cells.

12 Jun 2026

Silver nanoparticles enable precise DNA cutting and assembly

DNA is composed of long chains that act as the blueprint for living organisms. In genetic engineering, scientists cut DNA at specific sites and join the resulting fragments to other DNA sequences, enabling applications such as advanced crop breeding, genetic disease treatment, and the generation of animal models for drug discovery.

10 Jun 2026

Rice University receives CPRIT funding to advance cancer research

New funding from the Cancer Prevention and Research Institute of Texas (CPRIT) will help Rice University advance cancer research on several fronts, from strengthening a core genetic engineering facility that serves researchers across Texas to supporting new studies in cancer immunotherapy and ovarian cancer.

8 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

New ultrasound pacemaker design promises minimal recovery time for cardiac patients

MIT engineers have developed a noninvasive pacemaker that stimulates the heart using ultrasound. The design could one day provide a surgery-free alternative to traditional cardiac implants.

2 Jun 2026

Engineered regulatory T cells offer a path toward immunosuppression-free transplants

Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address chronic rejection and carries long-term side effects including infection, malignancy, and metabolic disorders.

8 May 2026

Glycocalyx modification boosts immune cell targeting against B lymphoma

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B lymphoma, addressing limitations such as high costs and restricted antigen specificity in current treatments.

25 Apr 2026

Bacterial vesicles emerge as powerful tools against antibiotic resistance

Antibiotic resistance is making bacterial infections harder to treat, demanding new therapeutic strategies. A new review highlights bacterial extracellular vesicles (BEVs) as promising nanoscale tools that can kill pathogens, block infection, enhance vaccines, and deliver drugs.

25 Apr 2026